The EMA at 20: Independence and transparency are the key to fulfilling the EMA's public health commitments
This article was originally published in Scrip
The EMA is ahead of the curve in addressing the concerns of patients, consumers and health professionals, but when it comes to independence, transparency and stimulating innovation, the agency still has a long way to go, say Tim Reed and Ancel.la Santos Quintano of Health Action International.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.